First evaluation: production process: a review of the dhr demonstrated that the mid-c system was manufactured, tested, and released according to apifix specifications.Risk assessment: at the time of this report (march 29, 2021), the company's incident rate of pain (not related to the surgical procedure) is (b)(4) which is well within the rate reported in the literature (cer -clinical evaluation report (b)(4)) the risk of pain is a known risk that has been assessed and found to be acceptable (b)(4).Event of pain addressed in the ifu warnings and precautions section: "metallic implants can loosen, fracture, corrode, migrate, or cause pain".
|